Trial · NCT03770208
RIB PAIN (Rib Fractures Treated With Parental Analgesia With Infused LidocaiNe)
NCT03770208, Not applicable, Unknown, Western University, Canada
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RIB PAIN (Rib Fractures Treated With Parental Analgesia With Infused LidocaiNe). Trials, record NCT03770208. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03770208
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RIB PAIN (Rib Fractures Treated With Parental Analgesia With Infused LidocaiNe)
- NCT number
- NCT03770208
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 26 participants, estimated
- Lead sponsor
- Western University, Canada
- Conditions
- Rib Fracture Multiple, Pain, Chest, Pain, Acute, Respiratory Failure, Thoracic Injuries, Trauma Chest
- Interventions
- Intervention: Lidocaine, Control: Standard Care + Placebo
- First posted
- 2018-12-10
- Last updated
- 2019-10-08
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Visual Analogue Scale (VAS) Score for Pain | Pain score to be measured before treatment initiation and every 6 hours thereafter until 72-96 hours. Scores will be performed by bedside nursing. | The primary outcome will be mean pain score calculated from the multiple VAS measures performed during Lidocaine infusions when the patient is at rest and with movement. The VAS for pain is a continuous numerical scale, demonstrated by a horizontal or vertical line, 10 cm long, with verbal descriptors at each end demonstrating the extremes, +/- a central descriptor. It is a scale essentially from 1 to 10, with one being no pain and 10 being the worst pain possible. Subjects mark on the line their approximate pain score by drawing a transecting line. This will be measured with a ruler from the start point on the line and recorded as a data point. |
| Secondary | Incidence of Protocol Non-adherence | Will be recorded by the ICU research assistants at the end of each patient's 72-96 hour study period. | Incidence of protocol violations with corresponding 95% confidence intervals. Descriptions of the deviations will be recorded. Types include, number of patients who received lidocaine that were not assigned to that group; number of patients who were assigned lidocaine and never received the study drug; non-weight based dosages of lidocaine; etc. |
| Secondary | Patient satisfaction as measured on the Visual Analogue Scale for Satisfaction | Research assistants will help administer the satisfaction survey to patients as soon as possible following completion of the 72-96 hour Lidocaine infusion. | The VAS for pain is a continuous numerical scale, demonstrated by a horizontal or vertical line, 10 cm long, with verbal descriptors at each end demonstrating the extremes, +/- a central descriptor. It is measured from one, representing not satisfied at all to ten, representing completely satisfied. Subjects mark on the line their approximate pain score by drawing a transecting line. This will be measured with a ruler from the start point on the line and recorded as a data point. Score will be performed on a VAS at the end of the treatment period. |
| Secondary | Incidence of respiratory failure requiring mechanical ventilation | Will be recorded by the ICU research assistants at the end of each patient's 72-96 hour study period. | Categorical data will be reported as percentages with corresponding 95% confidence intervals. |
| Secondary | Hospital length of stay | Will be recorded by the ICU research assistants at the end of each patient's 72-96 hour study period. | Continuous data will be reported as mean +/- standard deviation or median and interquartile range, depending on the distribution of each data point. |
| Secondary | ICU length of stay | Will be recorded by the ICU research assistants at the end of each patient's 72-96 hour study period. | Continuous data will be reported as mean +/- standard deviation or median and interquartile range, depending on the distribution of each data point. |
| Secondary | Incidence of Mortality | Will be recorded by the ICU research assistants at the end of each patient's 72-96 hour study period or when the mortality occurs. | Categorical data will be reported as percentages with corresponding 95% confidence intervals. |
| Secondary | Incidence of lidocaine toxicity/adverse events | Will be recorded by the ICU research assistants at the end of each patient's 72-96 hour study period. | Categorical data will be reported as percentages with corresponding 95% confidence intervals. Toxic symptoms will also be recorded. |
| Secondary | Treatment regimens (use of additional non-opioid analgesics): Medication type | Will be recorded by the ICU research assistants at the end of each patient's 72-96 hour study period. | Any non-opioid analgesic medications used will be recorded. Incidence of each medications' use will be reported as percentages with corresponding 95% confidence intervals. |
| Secondary | Treatment regimens (use of additional non-opioid analgesics): Dosages | Will be recorded by the ICU research assistants at the end of each patient's 72-96 hour study period. | Dosages of any non-opioid analgesic medications used will be recorded. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers19
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03770208
GET https://conductscience.org/api/trials/v1/NCT03770208/registered